Weil is advising Iodine Software, a leader in AI-powered clinical intelligence, in its acquisition by Waystar from shareholders led by Advent International for a total enterprise value of $1.25 billion. The transaction is anticipated to close by year-end 2025, subject to customary closing conditions and applicable regulatory approvals.

The Weil team is led by U.S. Private Equity Co-Head Ramona Nee and includes Private Equity partners Michael Messina and Frances Dales and associates Ryan Strassman, Ella Woodward and Reed Ruddick; Employment partner Xander Flynn-Tabloff and associate Michael Verdichizzi; Executive Compensation & Benefits partner Jennifer Britz and associate Emily Warren; U.S. Antitrust Co-Head Brianne Kucerik, counsel Carla Hine and associate Drew Cypher; Technology & IP Transactions partner Dennis Adams and associate Jeeyoon Chung; Privacy & Cybersecurity partner Liza Cotter and associate Dominic Farchione; Tax partners Noah Beck and Chayim Neubort and associate Grant Solomon; and Regulatory Transactions partner John O'Loughlin.